Control Bionics Limited
CBL.AX
Australian Securities Exchange0.08
AUD
+0.00
- -
Control Bionics Limited
CBL.AX
(Australian Securities Exchange)
Recent
price
0.08
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Control Bionics Limited Control Bionics Limited (ASX:CBL) is an Australian medical device company that develops, manufactures, and commercializes assistive communications technology systems for individuals with severe speech and motor impairments, including those affected by Motor Neurone Disease (MND), Amyotrophic Lateral Sclerosis (ALS), cerebral palsy, spinal cord injuries, and similar conditions; its core products include the patented NeuroNode wireless wearable sensor, which detects electromyography (EMG) signals from residual muscle activity to enable computer control for speech generation, email, texting, entertainment, and external devices such as wheelchairs and dining robots, alongside the NeuroNode Trilogy and NeuroNode Duo systems, EyeGaze Duo for integrated eye-tracking, Uno Touch portable speech-generating device, NeuroStrip for physiological monitoring in rehabilitation and sports performance, and accessories like mounting systems and switches compatible with Windows and iOS platforms including the Oskol 2 variant. Founded in 2005 and headquartered in Cremorne, Victoria, Australia, the company operates primarily in North America, with additional presence in Australia, the United Kingdom, Ireland, Singapore, and Japan, deriving a majority of revenue from North America through channels like Medicare, Medicaid, Veterans Health Administration, private insurance, and Australia's National Disability Insurance Scheme (NDIS). Recent developments include an exclusive distribution partnership with Smart Box Ltd in September 2024 to market NeuroNode in the UK and Ireland, a strategic collaboration with Apple's Brain-Computer Interface (BCI) Protocol announced in November 2025 to enhance commercial growth and technological integration, executive appointments such as Shannon Boothroyd as Chief Financial Officer in May 2024 and ongoing leadership under CEO Jeremy Steele since early 2023, and continued expansion of the NeuroStrip technology into physical rehabilitation and wearables applications.